Agilent Technologies Inc
$
72.93
0.28 (0.39%)
| Volume: | 493,812 | Avg Vol (1m): | 2,848,333 |
| Market Cap $: | 23.10 Bil | Enterprise Value $: | 22.74 Bil |
| P/E (TTM): | 21.01 | P/B: | 4.58 |
| Earnings Power Value | 23.84 |
| Net Current Asset Value | -0.26 |
| Tangible Book | 4.6 |
| Projected FCF | 33.09 |
| Median P/S Value | 47.82 |
| Graham Number | 18.97 |
| Peter Lynch Value | 70.57 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 7/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 1.20 |
Cash-To-Debt ranked
lower than
62.07%
of
261
companies
in the
Diagnostics & Research
industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
A:
1.2
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 0.63, Med: 1.25, Max: 10000
Current: 1.2
|
| Equity-to-Asset | 0.57 |
Equity-to-Asset ranked
lower than
64.85%
of
239
companies
in the
Diagnostics & Research
industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
A:
0.57
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: 0.31, Med: 0.51, Max: 0.71
Current: 0.57
|
| Debt-to-Equity | 0.35 |
Debt-to-Equity ranked
lower than
60.37%
of
164
companies
in the
Diagnostics & Research
industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
A:
0.35
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: 0.02, Med: 0.42, Max: 1.31
Current: 0.35
|
| Debt-to-EBITDA | 1.45 |
Debt-to-EBITDA ranked
lower than
50.86%
of
116
companies
in the
Diagnostics & Research
industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
A:
1.45
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: 1.45, Med: 2.14, Max: 11.3
Current: 1.45
|
| Interest Coverage | 13.24 |
Interest Coverage ranked
lower than
66.87%
of
163
companies
in the
Diagnostics & Research
industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
A:
13.24
Ranked among companies with meaningful Interest Coverage only.
|
Interest Coverage range over the past 10 years
Min: 0.53, Med: 8.23, Max: 13.24
Current: 13.24
|
| Piotroski F-Score | 7 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 4.85 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.26 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 25.5%
WACC 9.48%
| ||
Profitability & Growth : 8/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 18.73 |
Operating Margin ranked
higher than
88.43%
of
242
companies
in the
Diagnostics & Research
industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
A:
18.73
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: 1.05, Med: 13.79, Max: 18.88
Current: 18.73
|
| Net Margin % | 22.26 |
Net Margin ranked
higher than
65.15%
of
241
companies
in the
Diagnostics & Research
industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
A:
22.26
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -0.69, Med: 13.06, Max: 22.26
Current: 22.26
|
| ROE % | 23.36 |
ROE ranked
higher than
61.16%
of
242
companies
in the
Diagnostics & Research
industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
A:
23.36
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -1.22, Med: 12.51, Max: 26.86
Current: 23.36
|
| ROA % | 12.80 |
ROA ranked
higher than
62.60%
of
262
companies
in the
Diagnostics & Research
industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
A:
12.8
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -0.42, Med: 6.49, Max: 12.8
Current: 12.8
|
| ROC (Joel Greenblatt) % | 77.59 |
ROC (Joel Greenblatt) ranked
higher than
89.58%
of
259
companies
in the
Diagnostics & Research
industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
A:
77.59
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: 7.79, Med: 44.69, Max: 83.45
Current: 77.59
|
| 3-Year Total Revenue Growth Rate | 6.80 |
3-Year Revenue Growth Rate ranked
lower than
51.10%
of
182
companies
in the
Diagnostics & Research
industry.
Industry Max: 371, Med: 4.8, Min: -100
A:
7.8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: -22.9, Med: 4.4, Max: 18.4
Current: 7.8
|
| 3-Year Total EBITDA Growth Rate | 15.50 |
3-Year EBITDA Growth Rate ranked
higher than
62.36%
of
178
companies
in the
Diagnostics & Research
industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
A:
16.7
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -11.9, Max: 76.6
Current: 16.7
|
| 3-Year EPS w/o NRI Growth Rate | -9.50 |
3-Year EPS w/o NRI Growth Rate ranked
higher than
87.12%
of
163
companies
in the
Diagnostics & Research
industry.
Industry Max: 138.7, Med: 10.1, Min: -301
A:
-9.5
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
|
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -34.1, Max: 135.6
Current: -9.5
|
» A's 30-Y Financials
Financials (Next Earnings Date: 2019-08-14)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NYSE:A
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Medical Diagnostics & Research » Diagnostics & Research   NAICS : 334516   SIC : 3825 |
| Compare | NAS:IDXX XSWX:LONN NYSE:MTD NYSE:IQV NYSE:LH TSE:6869 NYSE:WAT SHSE:603259 NYSE:DGX NAS:EXAS XTER:SRT NAS:DXCM XPAR:BIM NYSE:PKI NYSE:BIO NYSE:QGEN XPAR:ERF NAS:ICLR NAS:GH NAS:BRKR |
| Traded in other countries | AG8.Germany 0HAV.UK |
| Address | 5301 Stevens Creek Boulevard, Santa Clara, CA, USA, 95051 |
| Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading health-care firm. Today, Agilent's measurement technologies serve a broad base of customers within three operating segments: life science and applied equipment (49% of sales), cross lab (which includes consumables and services at 34%), and diagnostics and genomics (17%). The United States and Europe account for 34% and 27% of revenue, respectively, with China and Japan accounting for the majority of remaining sales. Agilent is headquartered in California. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 21.01 |
PE Ratio ranked
lower than
93.81%
of
113
companies
in the
Diagnostics & Research
industry.
Industry Max: 1345, Med: 35, Min: 0.33
A:
21.01
Ranked among companies with meaningful PE Ratio only.
|
PE Ratio range over the past 10 years
Min: 5.2, Med: 20, Max: 126.81
Current: 21.01
|
| Forward PE Ratio | 23.75 |
Forward P/E ranked
lower than
65.00%
of
40
companies
in the
Diagnostics & Research
industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
A:
23.75
Ranked among companies with meaningful Forward P/E only.
| N/A |
| PE Ratio without NRI | 21.01 |
PE without NRI ranked
lower than
93.81%
of
113
companies
in the
Diagnostics & Research
industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
A:
21.01
Ranked among companies with meaningful PE without NRI only.
|
PE without NRI range over the past 10 years
Min: 5.2, Med: 23.59, Max: 126.81
Current: 21.01
|
| Price-to-Owner-Earnings | 29.24 |
Price-to-Owner-Earnings ranked
higher than
61.84%
of
76
companies
in the
Diagnostics & Research
industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
A:
29.24
Ranked among companies with meaningful Price-to-Owner-Earnings only.
|
Price-to-Owner-Earnings range over the past 10 years
Min: 6.01, Med: 26.11, Max: 194.42
Current: 29.24
|
| PB Ratio | 4.58 |
PB Ratio ranked
lower than
56.33%
of
245
companies
in the
Diagnostics & Research
industry.
Industry Max: 270, Med: 4.02, Min: 0.15
A:
4.58
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 1.22, Med: 2.89, Max: 5.34
Current: 4.58
|
| PS Ratio | 4.69 |
PS Ratio ranked
lower than
58.70%
of
230
companies
in the
Diagnostics & Research
industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
A:
4.69
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 0.59, Med: 3.07, Max: 7.73
Current: 4.69
|
| Price-to-Free-Cash-Flow | 26.55 |
Price-to-Free-Cash-Flow ranked
lower than
51.25%
of
80
companies
in the
Diagnostics & Research
industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
A:
26.55
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
|
Price-to-Free-Cash-Flow range over the past 10 years
Min: 5.4, Med: 20.41, Max: 68.05
Current: 26.55
|
| Price-to-Operating-Cash-Flow | 22.77 |
Price-to-Operating-Cash-Flow ranked
lower than
56.70%
of
97
companies
in the
Diagnostics & Research
industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
A:
22.77
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
|
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 4.31, Med: 15.24, Max: 39.2
Current: 22.77
|
| EV-to-EBIT | 22.22 |
EV-to-EBIT ranked
higher than
53.39%
of
118
companies
in the
Diagnostics & Research
industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
A:
22.22
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: 4.9, Med: 22.2, Max: 249.8
Current: 22.22
|
| EV-to-EBITDA | 18.35 |
EV-to-EBITDA ranked
higher than
52.27%
of
132
companies
in the
Diagnostics & Research
industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
A:
18.35
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: 4, Med: 16.7, Max: 31.7
Current: 18.35
|
| EV-to-Revenue | 4.53 |
EV-to-Revenue ranked
lower than
54.55%
of
242
companies
in the
Diagnostics & Research
industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
A:
4.53
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 0.7, Med: 3, Max: 7.6
Current: 4.53
|
| PEG Ratio | 1.69 |
PEG Ratio ranked
lower than
100.00%
of
48
companies
in the
Diagnostics & Research
industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
A:
1.69
Ranked among companies with meaningful PEG Ratio only.
|
PEG Ratio range over the past 10 years
Min: 0.08, Med: 0.95, Max: 40
Current: 1.69
|
| Shiller PE Ratio | 34.60 |
Shiller PE Ratio ranked
higher than
69.23%
of
39
companies
in the
Diagnostics & Research
industry.
Industry Max: 459.08, Med: 52.49, Min: 10.19
A:
34.6
Ranked among companies with meaningful Shiller PE Ratio only.
|
Shiller PE Ratio range over the past 10 years
Min: 9.84, Med: 24.11, Max: 46.42
Current: 34.6
|
| Current Ratio | 3.41 |
Current Ratio ranked
higher than
60.80%
of
250
companies
in the
Diagnostics & Research
industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
A:
3.41
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 1.61, Med: 2.63, Max: 4.08
Current: 3.41
|
| Quick Ratio | 2.82 |
Quick Ratio ranked
higher than
60.40%
of
250
companies
in the
Diagnostics & Research
industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
A:
2.82
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 1.04, Med: 2.17, Max: 3.44
Current: 2.82
|
| Days Inventory | 101.65 |
Days Inventory ranked
lower than
56.86%
of
204
companies
in the
Diagnostics & Research
industry.
Industry Max: 917.88, Med: 79.76, Min: 0.37
A:
101.65
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 92.05, Med: 99.64, Max: 191.04
Current: 101.65
|
| Days Sales Outstanding | 59.56 |
Days Sales Outstanding ranked
higher than
59.31%
of
204
companies
in the
Diagnostics & Research
industry.
Industry Max: 521.64, Med: 67.51, Min: 1
A:
59.56
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 47.45, Med: 55.63, Max: 84.27
Current: 59.56
|
| Days Payable | 50.42 |
Days Payable ranked
lower than
62.57%
of
187
companies
in the
Diagnostics & Research
industry.
Industry Max: 981.81, Med: 63.34, Min: 1
A:
50.42
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 46.79, Med: 53.58, Max: 79.36
Current: 50.42
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| Dividend Yield % | 0.85 |
Trailing Dividend Yield ranked
lower than
52.89%
of
121
companies
in the
Diagnostics & Research
industry.
Industry Max: 10.16, Med: 0.81, Min: 0.07
A:
0.85
Ranked among companies with meaningful Trailing Dividend Yield only.
|
Trailing Dividend Yield range over the past 10 years
Min: 0.31, Med: 1.01, Max: 1.42
Current: 0.85
|
| Dividend Payout Ratio | 0.18 |
Dividend Payout Ratio ranked
lower than
72.86%
of
70
companies
in the
Diagnostics & Research
industry.
Industry Max: 6.35, Med: 0.32, Min: 0.03
A:
0.18
Ranked among companies with meaningful Dividend Payout Ratio only.
|
Dividend Payout Ratio range over the past 10 years
Min: 0.09, Med: 0.33, Max: 0.77
Current: 0.18
|
| 3-Year Dividend Growth Rate (Per Share) | 14.20 |
3-Year Dividend Growth Rate ranked
lower than
100.00%
of
36
companies
in the
Diagnostics & Research
industry.
Industry Max: 77.2, Med: 9.9, Min: -100
A:
14.2
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
|
3-Year Dividend Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 14.2
Current: 14.2
|
| Forward Dividend Yield % | 0.90 |
Forward Dividend Yield ranked
lower than
55.75%
of
113
companies
in the
Diagnostics & Research
industry.
Industry Max: 10.53, Med: 1.1, Min: 0.07
A:
0.9
Ranked among companies with meaningful Forward Dividend Yield only.
| N/A |
| Yield-on-Cost (5-Year) % | 1.07 |
Yield-on-Cost (5y) ranked
lower than
53.52%
of
142
companies
in the
Diagnostics & Research
industry.
Industry Max: 12, Med: 1.41, Min: 0.08
A:
1.07
Ranked among companies with meaningful Yield-on-Cost (5y) only.
|
Yield-on-Cost (5y) range over the past 10 years
Min: 0.38, Med: 1.24, Max: 1.74
Current: 1.07
|
| 3-Year Share Buyback Rate | 1.40 |
3-Year Share Buyback Rate ranked
higher than
95.00%
of
180
companies
in the
Diagnostics & Research
industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
A:
1.4
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -2.5, Med: 1.25, Max: 11.4
Current: 1.4
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 15.89 |
Price-to-Tangible-Book ranked
lower than
81.16%
of
207
companies
in the
Diagnostics & Research
industry.
Industry Max: 272.36, Med: 6.46, Min: 0.21
A:
15.89
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 1.1, Med: 4.07, Max: 18.88
Current: 15.89
|
| Price-to-Projected-FCF | 2.21 |
Price-to-Intrinsic-Value-Projected-FCF ranked
higher than
52.00%
of
75
companies
in the
Diagnostics & Research
industry.
Industry Max: 449, Med: 2.41, Min: 0.47
A:
2.21
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
|
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.6, Med: 1.32, Max: 3.73
Current: 2.21
|
| Price-to-Median-PS-Value | 1.53 |
Price-to-Median-PS-Value ranked
lower than
90.16%
of
193
companies
in the
Diagnostics & Research
industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
A:
1.53
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.23, Med: 0.61, Max: 2.41
Current: 1.53
|
| Price-to-Peter-Lynch-Fair-Value | 1.04 |
Price-to-Peter-Lynch-Fair-Value ranked
lower than
100.00%
of
30
companies
in the
Diagnostics & Research
industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
A:
1.04
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
|
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.3, Med: 1.03, Max: 11.7
Current: 1.04
|
| Price-to-Graham-Number | 3.85 |
Price-to-Graham-Number ranked
lower than
94.74%
of
76
companies
in the
Diagnostics & Research
industry.
Industry Max: 49.42, Med: 3.98, Min: 0.39
A:
3.85
Ranked among companies with meaningful Price-to-Graham-Number only.
|
Price-to-Graham-Number range over the past 10 years
Min: 0.84, Med: 2.32, Max: 9.2
Current: 3.85
|
| Earnings Yield (Joel Greenblatt) % | 4.50 |
Earnings Yield (Greenblatt) ranked
higher than
79.25%
of
265
companies
in the
Diagnostics & Research
industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
A:
4.5
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: 0.4, Med: 4.5, Max: 20.2
Current: 4.5
|
| Forward Rate of Return (Yacktman) % | 22.76 |
Forward Rate of Return ranked
lower than
54.29%
of
70
companies
in the
Diagnostics & Research
industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
A:
22.76
Ranked among companies with meaningful Forward Rate of Return only.
|
Forward Rate of Return range over the past 10 years
Min: -10.2, Med: 18.6, Max: 36.5
Current: 22.76
|
More Statistics
| Revenue (TTM) (Mil) $ | 5,019 |
| EPS (TTM) $ | 3.48 |
| Beta | 1.33 |
| Volatility % | 27.71 |
| 52-Week Range $ | 60.42 - 82.27 |
| Shares Outstanding (Mil) | 315.99 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 7 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | N |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | Y |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | N |